Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...

Stroke survivors were more likely to have little or no disability after 90 days if a clot was removed from a large brain artery followed by the injection of the clot-dissolving medication tenecteplase ...

The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...

BASEL, Switzerland—Multiple randomized trials presented last week at the European Stroke Organisation Conference (ESOC) 2024 have bolstered the case that tenecteplase (TNK) is an effective—if not ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

The MarketWatch News Department was not involved in the creation of this content. The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for ...

DALLAS, Feb. 1, 2024 — Compared with the standard clot-busting medication alteplase, the newer clot-buster tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) ...

Please provide your email address to receive an email when new articles are posted on . The findings were presented in a poster at the American College of Allergy, Asthma & Immunology Annual ...

Two randomized trials found that intra-arterial urokinase and tenecteplase did not improve functional outcomes after mechanical thrombectomy in selected stroke patients. However, these results do not ...